Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL2487211

CC(=O)Nc1cccc(-c2n[nH]c3ncc4c(c23)CCNC4)c1.O=C(O)C(F)(F)F

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTK P33981 2/20 0.41
MAPK8 P45983 2/20 0.41
PARP1 P09874 3/20 0.39
CHEK1 O14757 2/20 0.39
FGFR1 P11362 1/20 0.39
NEK2 P51955 1/20 0.39
MAPK15 Q8TD08 1/20 0.39
LRRK2 Q5S007 1/20 0.38
PDE5A O76074 1/20 0.38
PDE1A P54750 1/20 0.38
PDE1B Q01064 1/20 0.38
PDE3B Q13370 1/20 0.38
PDE1C Q14123 1/20 0.38
PDE3A Q14432 1/20 0.38
JAK3 P52333 1/20 0.38
MELK Q14680 1/20 0.38
DYRK1A Q13627 1/20 0.38
DYRK1B Q9Y463 1/20 0.38
NPC1 O15118 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2805911 0.94 TTK (0.45) TTKMAPK8PARP1CHEK1FGFR1
Trifluoroacetic Acid SCHEMBL2490575 0.84 MAP2K4 (0.42) TTKMAPK8PARP1CHEK1FGFR1
SCHEMBL2804970 0.77 MAP2K4 (0.47) TTKMAPK8PARP1CHEK1FGFR1
SCHEMBL12315721 0.77 HTR7 (0.49)
Hydrochloric Acid SCHEMBL2486184 0.76 HTR7 (0.48)
Trifluoroacetic Acid SCHEMBL2485470 0.74 ATR (0.31)
SCHEMBL2486503 0.74 MKNK1 (0.41) TTKMAPK8PARP1LRRK2PDE5A
Trifluoroacetic Acid SCHEMBL2111967 0.70 NPC1 (0.43) NPC1TSHRRAB9ASMN1; SMN2NQO2
Trifluoroacetic Acid SCHEMBL3278005 0.70 SSTR4 (0.42) NPC1TSHRRAB9ASMN1; SMN2NQO2
SCHEMBL2804159 0.68 TRPV1 (0.49) NPC1RAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
EP-2379551-A1 SUBSTITUTED PYRAZOLO [3, 4-B]PYRIDINE COMPOUNDS ArQule, Inc. (US) 2011-10-26 EP disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 TTK 3440/4885MAPK8 2818/4885PARP1 564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.